To assess whether we could observe induction of PAI1 in the serum of patients with EGFR mutant tumors undergoing EGFR TKI treatment, we performed a retrospective study in NSCLC patients (n = 42) with EGFR-mutant tumors. Here, EGFR is linked to non-small cell lung carcinoma.